Evidence map›Paper›PMID 29261005›Full record

Observational studyCancer biology & therapy2018

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.

Baorang Zhu, Jing Li, Qiaosheng Xie, Liyan Diao, Lvhua Gai, Wuwei Yang

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer biology & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Baorang Zhua Department of Oncology Minimally Invasive , The 307th Hospital of PLA, Affiliated Hospital of Military Medical Sciences , Beijing , China.
Jing Lia Department of Oncology Minimally Invasive , The 307th Hospital of PLA, Affiliated Hospital of Military Medical Sciences , Beijing , China.
Qiaosheng Xiea Department of Oncology Minimally Invasive , The 307th Hospital of PLA, Affiliated Hospital of Military Medical Sciences , Beijing , China.
Liyan Diaoa Department of Oncology Minimally Invasive , The 307th Hospital of PLA, Affiliated Hospital of Military Medical Sciences , Beijing , China.
Lvhua Gaia Department of Oncology Minimally Invasive , The 307th Hospital of PLA, Affiliated Hospital of Military Medical Sciences , Beijing , China.
Wuwei Yanga Department of Oncology Minimally Invasive , The 307th Hospital of PLA, Affiliated Hospital of Military Medical Sciences , Beijing , China.
307th Hospital of Chinese People’s Liberation Army · CN302 Military Hospital of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcomas are rare but malignant tumors with high risks of local recurrence and distant metastasis. Anti-angiogenic therapy is a potential strategy against un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety and efficacy of apatinib, an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, in patients with advanced sarcoma. Thirty-one patients who received initial apatinib between September 2015 and August 2016 were retrospectively reviewed. Among them, 19 (61.3%) patients were heavily pretreated with two or more lines of cytotoxic chemotherapy. Apatinib was given at a start-dose of 425 mg qd. During therapy, 9 (29.0%) patients required dose interruption and 7 (22.6%) needed dose reduction, and the mean dosage of apatinib was 372.9 ± 68.4 mg/day. In the study cohort, one patient was treated as adjunctive therapy and 6 patients stopped treatment before radiographic response assessment. Thus, 24 patients were eligible for tumor response evaluation. The objective response rate was 33.3% and clinical benefit rate was as high as 75.0%. The progression free survival was 4.25 (95% confidence interval [CI], 2.22-5.11) months, whereas the overall survival was 9.43 (95% CI, 6.64-18.72) months. Compared with other histological subtypes, leiomyosarcoma did not show significant survival benefits. Most of the adverse events (AEs) were at grade 1 or 2. The main grade 3 AEs were hypertension (6.5%), hand foot skin reaction (6.5%), and diarrhea (3.2%). In conclusion, apatinib showed promising efficacy and acceptable safety profile in metastatic or recurrent sarcoma, giving rationale clinical evidence to conduct clinical trials.

Indexed as

AdolescentAdultAgedAntineoplastic AgentsBone NeoplasmsChildChild, PreschoolDiarrheaFemaleHand-Foot SyndromeHumansHypertensionKaplan-Meier EstimateLeiomyosarcomaMagnetic Resonance ImagingMaleAntineoplastic AgentsapatinibKDR protein, humanPyridinesVascular Endothelial Growth Factor Receptor-2apatinibefficacyobservational studyosteosarcomasafetySoft tissue sarcomatargeted therapy

Identifiers

PMID29261005
PMCPMC5790336
OpenAlexW2775931026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.